Detalles de la búsqueda
1.
Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3-18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study).
EClinicalMedicine
; 63: 102160, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37649806
2.
Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20164251
Resultados
1 -
2
de 2
1
Próxima >
>>